I am...
I am...
The number of grants awarded by the Histiocytosis Association varies each year. It is determined by a variety of factors including, but not limited to, the quality of eligible applications received and the availability of funds.
Use the filters below to see information for all of the research projects the Association has funded since 1992.
To filter by year and disease type, select the year first.
- All
- HLH/FEL/FHL
- LCH
- Rare Histiocytic Disorders and Other Topics
- RDD
Modeling Langerhans cell Histiocytosis with patient-derived iPSCs
Principal Investigator Dr. Giulio Abagnale St.Anna Children’s Cancer Research Institute Vienna, Austria Date of Award December 2021…
Role of the immune checkpoint TIM-3 in the pathogenesis of non-classical HLH
Principal Investigator Dr. Fernando Sepulveda Imagine Institute Paris, FR Date of Award December 2021 Amount of Award…
Identifying novel CSF Biomarkers for the Diagnosis of Isolated CNS Hemophagocytic Lymphohistiocytosis
Principal Investigator Dr. Sharat Chandra Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio USA Date of Award December…
2020 Grant Cycle
Due to COVID-19 slowing down research and hindering access to laboratories in the Spring of 2020, the…
Excessive IL-10 Potentiates IL-18 to Cooperatively Drive Severe Secondary HLH/MAS-like Disease and Hyper-inflammaphagocytic Macrophage Polarization in Mouse Models.
Gang Huang Cincinnati Children’s Hospital Medical Center, Cincinnati, OH USA
Transcriptional dysregulation of myeloid cells with MAP kinase pathway mutations
Matthew Collin Newcastle University, Newcastle upon Tyne, UK
Identification of a microRNA expression signature for diagnosis and monitoring of treatment response in Erdheim-Chester disease and its role in disease pathogenesis
Ofer Shpilberg Assuta Medical Centers, Tel-Aviv, Israel
Mapping and understanding the heterogeneity of Langerhans cell histiocytosis using single-cell analysis
Florent Ginhoux Singapore Immunology Network (SIgN) / A*STAR, Singapore
Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
Melissa Hines St Jude Children’s Research Hospital, Memphis, TN USA